The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
Open accessAbstract
BACKGROUND: BG-12 (dimethyl fumarate) was shown to have antiinflammatory and cytoprotective properties in preclinical experiments and to result in significant reductions in disease activity on magnetic resonance imaging (MRI) in a phase 2, placebo-controlled study involving patients with relapsing-remitting multiple sclerosis. METHODS: We conducted a randomized, double-blind, placebo-controlled phase 3 study involving patients with relapsing-remitting multiple sclerosis. Patients were randomly assigned to receive oral BG-12 at a dose of 240 mg twice daily, BG-12 at a dose of 240 mg three times daily, or placebo. The primary end point was the proportion of patients who had a relapse by 2 years. Other end points included the annualized relapse rate, the time to confirmed progression of disability, and findings on MRI. RESULTS: The estimated proportion of patients who had a relapse was significantly lower in the two BG-12 groups than in the placebo group (27% with BG-12 twice daily and 26% with BG-12 thrice daily vs. 46% with placebo, P<0.001 for both comparisons). The annualized relapse rate at 2 years was 0.17 in the twice-daily BG-12 group and 0.19 in the thrice-daily BG-12 group, as compared with 0.36 in the placebo group, representing relative reductions of 53% and 48% with the two BG-12 regimens, respectively (P<0.001 for the comparison of each BG-12 regimen with placebo). The estimated proportion of patients with confirmed progression of disability was 16% in the twice-daily BG-12 group, 18% in the thrice-daily BG-12 group, and 27% in the placebo group, with significant relative risk reductions of 38% with BG-12 twice daily (P=0.005) and 34% with BG-12 thrice daily (P=0.01). BG-12 also significantly reduced the number of gadolinium-enhancing lesions and of new or enlarging T(2)-weighted hyperintense lesions (P<0.001 for the comparison of each BG-12 regimen with placebo). Adverse events associated with BG-12 included flushing and gastrointestinal events, such as diarrhea, nausea, and upper abdominal pain, as well as decreased lymphocyte counts and elevated liver aminotransferase levels. CONCLUSIONS: In patients with relapsing-remitting multiple sclerosis, both BG-12 regimens, as compared with placebo, significantly reduced the proportion of patients who had a relapse, the annualized relapse rate, the rate of disability progression, and the number of lesions on MRI. (Funded by Biogen Idec; DEFINE ClinicalTrials.gov number, NCT00420212.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria
Polman, C. H., Reingold, S. C., Banwell, B., Clanet, M., Cohen, J. A., Filippi, M., Fujihara, K., Havrdova, E., Hutchinson, M., Kappos, L., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22366 · Cited by 9,802
Self-citationDiagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
Polman, C. H., Reingold, S. C., Edan, G., Filippi, M., Hartung, H., Kappos, L., Lublin, F. D., Metz, L. M., McFarland, H. F., O'Connor, P. W., et al. (2005) · Annals of Neurology · doi:10.1002/ana.20703 · Cited by 5,017
Self-citationDefining the clinical course of multiple sclerosis: Results of an international survey
Lublin, F. D., Reingold, S. C., & National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis* (1996) · Neurology · doi:10.1212/wnl.46.4.907 · Cited by 3,686
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
Polman, C. H., O'Connor, P. W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D. H., Phillips, J. T., Lublin, F. D., Giovannoni, G., Wajgt, A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044397 · Cited by 3,386
Self-citationA Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Kappos, L., Radue, E.-W., O'Connor, P., Polman, C., Hohlfeld, R., Calabresi, P., Selmaj, K., Agoropoulou, C., Leyk, M., Zhang-Auberson, L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909494 · Cited by 2,644
Self-citationIntramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis
Jacobs, L. D., Cookfair, D. L., Rudick, R. A., Herndon, R. M., Richert, J. R., Salazar, A. M., Fischer, J. S., Goodkin, D. E., Granger, C. V., Simon, J. H., et al. (1996) · Annals of Neurology · doi:10.1002/ana.410390304 · Cited by 2,450
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Cohen, J. A., Barkhof, F., Comi, G., Hartung, H.-P., Khatri, B. O., Montalban, X., Pelletier, J., Capra, R., Gallo, P., Izquierdo, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907839 · Cited by 2,204
Self-citationJohnson, K. P., Brooks, B. R., Cohen, J. A., Ford, C. C., Goldstein, J., Lisak, R. P., Myers, L. W., Panitch, H. S., Rose, J. W., Schiffer, R. B., et al. (1995) · Neurology · doi:10.1212/wnl.45.7.1268 · Cited by 1,898
Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
Fox, R. J., Miller, D. H., Phillips, J. T., Hutchinson, M., Havrdova, E., Kita, M., Yang, M., Raghupathi, K., Novas, M., Sweetser, M. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206328 · Cited by 1,355
Self-citation
Cited by
Targeting the KEAP1-NRF2 system to prevent kidney disease progression
Nezu, M., Suzuki, N., & Yamamoto, M. (2017) · American Journal of Nephrology · doi:10.1159/000475890 · Cited by 3,447
Targeting oxidative stress in disease: Promise and limitations of antioxidant therapy
Forman, H. J., & Zhang, H. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00233-1 · Cited by 2,900
The KEAP1-NRF2 system: a thiol-based sensor-effector apparatus for maintaining redox homeostasis
Yamamoto, M., Kensler, T. W., & Motohashi, H. (2018) · Physiological Reviews · doi:10.1152/physrev.00023.2017 · Cited by 1,968
Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription
Kobayashi, E. H., Suzuki, T., Funayama, R., Nagashima, T., Hayashi, M., Sekine, H., Tanaka, N., Moriguchi, T., Motohashi, H., Nakayama, K., et al. (2016) · Nature Communications · doi:10.1038/ncomms11624 · Cited by 1,878
Filippi, M., Bar-Or, A., Piehl, F., Preziosa, P., Solari, A., Vukusic, S., & Rocca, M. A. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0041-4 · Cited by 1,562
Self-citationThe Molecular Mechanisms Regulating the KEAP1-NRF2 Pathway
Baird, L., & Yamamoto, M. (2020) · Molecular and Cellular Biology · doi:10.1128/mcb.00099-20 · Cited by 1,542
An Overview of Nrf2 Signaling Pathway and Its Role in Inflammation
Saha, S., Buttari, B., Panieri, E., Profumo, E., & Saso, L. (2020) · Molecules · doi:10.3390/molecules25225474 · Cited by 1,388
Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
Fox, R. J., Miller, D. H., Phillips, J. T., Hutchinson, M., Havrdova, E., Kita, M., Yang, M., Raghupathi, K., Novas, M., Sweetser, M. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206328 · Cited by 1,355
Self-citationThe emerging role of the Nrf2–Keap1 signaling pathway in cancer
Jaramillo, M. C., & Zhang, D. D. (2013) · Genes & Development · doi:10.1101/gad.225680.113 · Cited by 1,297
Diagnosis and Treatment of Multiple Sclerosis: A Review
McGinley, M. P., Goldschmidt, C. H., & Rae-Grant, A. D. (2021) · JAMA · doi:10.1001/jama.2020.26858 · Cited by 1,205
Multiple Sclerosis: Current Knowledge and Future Outlook
Kamm, C. P., Uitdehaag, B. M., & Polman, C. H. (2014) · European Neurology · doi:10.1159/000360528 · Cited by 1,010
Diabetic Nephropathy: Challenges in Pathogenesis, Diagnosis, and Treatment
Samsu, N. (2021) · BioMed Research International · doi:10.1155/2021/1497449 · Cited by 1,001
Treatment of Multiple Sclerosis: A Review
Hauser, S. L., & Cree, B. A. C. (2020) · The American Journal of Medicine · doi:10.1016/j.amjmed.2020.05.049 · Cited by 969
The impact of oxidative stress and inflammation on RPE degeneration in non-neovascular AMD
Datta, S., Cano, M., Ebrahimi, K., Wang, L., & Handa, J. T. (2017) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.03.002 · Cited by 802
The Keap1–Nrf2–ARE Pathway As a Potential Preventive and Therapeutic Target: An Update
Lu, M., Ji, J., Jiang, Z., & You, Q. (2016) · Medicinal Research Reviews · doi:10.1002/med.21396 · Cited by 790
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
Montalban, X., Gold, R., Thompson, A. J., Otero-Romero, S., Amato, M. P., Chandraratna, D., Clanet, M., Comi, G., Derfuss, T., Fazekas, F., et al. (2018) · Multiple Sclerosis Journal · doi:10.1177/1352458517751049 · Cited by 712
Self-citationBuendia, I., Michalska, P., Navarro, E., Gameiro, I., Egea, J., & León, R. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.11.003 · Cited by 678
Kirkham, P. A., & Barnes, P. J. (2013) · Chest · doi:10.1378/chest.12-2664 · Cited by 685
Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine Approach
Cuadrado, A., Manda, G., Hassan, A., Alcaraz, M. J., Barbas, C., Daiber, A., Ghezzi, P., León, R., López, M. G., Oliva, B., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014753 · Cited by 632
“Two phase III clinical trials, DEFINE and CONFIRM, substantiated these results (Fox et al., 2012; Gold et al., 2012).”
ResultConfavreux, C., O'Connor, P., Comi, G., Freedman, M. S., Miller, A. E., Olsson, T. P., Wolinsky, J. S., Bagulho, T., Delhay, J.-L., Dukovic, D., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70308-9 · Cited by 579
Self-citationTargeting immunometabolism as an anti-inflammatory strategy
Pålsson-McDermott, E. M., & O’Neill, L. A. J. (2020) · Cell Research · doi:10.1038/s41422-020-0291-z · Cited by 577
Iron and neurodegeneration in the multiple sclerosis brain
Hametner, S., Wimmer, I., Haider, L., Pfeifenbring, S., Brück, W., & Lassmann, H. (2013) · Annals of Neurology · doi:10.1002/ana.23974 · Cited by 519
Oxidative stress-based therapeutics in COPD
Barnes, P. J. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101544 · Cited by 497
Ghosh, S., Banerjee, S., & Sil, P. C. (2015) · Food and Chemical Toxicology · doi:10.1016/j.fct.2015.05.022 · Cited by 491
The experimental autoimmune encephalomyelitis (EAE) model of MS
(2014) · Handbook of Clinical Neurology · doi:10.1016/b978-0-444-52001-2.00008-x · Cited by 464
Holmström, K. M., Baird, L., Zhang, Y., Hargreaves, I., Chalasani, A., Land, J. M., Stanyer, L., Yamamoto, M., Dinkova-Kostova, A. T., & Abramov, A. Y. (2013) · Biology Open · doi:10.1242/bio.20134853 · Cited by 448
Multiple Sclerosis: Current and Emerging Disease-Modifying Therapies and Treatment Strategies
Wingerchuk, D. M., & Carter, J. L. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.11.002 · Cited by 416
Activators and inhibitors of NRF2: a review of their potential for clinical development
Robledinos-Antón, N., Fernández-Ginés, R., Manda, G., & Cuadrado, A. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/9372182 · Cited by 413
Mitochondrial Diseases of the Brain
Chaturvedi, R. K., & Flint Beal, M. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.03.018 · Cited by 413
Suzuki, T., & Yamamoto, M. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.r117.800169 · Cited by 400
New anti-inflammatory targets for chronic obstructive pulmonary disease
Barnes, P. J. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4025 · Cited by 392
The Keap1–Nrf2 system in cancers: stress response and anabolic metabolism
Mitsuishi, Y., Motohashi, H., & Yamamoto, M. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00200 · Cited by 392
NRF2-regulation in brain health and disease: Implication of cerebral inflammation
Sandberg, M., Patil, J., D'Angelo, B., Weber, S. G., & Mallard, C. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.11.004 · Cited by 390
The Role of Astrocytes in Multiple Sclerosis
Ponath, G., Park, C., & Pitt, D. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00217 · Cited by 359
Multiple sclerosis: Pathology, diagnosis and treatments
Huang, W.-J., Chen, W.-W., & Zhang, X. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.4410 · Cited by 351
An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis
Garg, N., & Smith, T. W. (2015) · Brain and Behavior · doi:10.1002/brb3.362 · Cited by 348
Treatment of multiple sclerosis — success from bench to bedside
Tintore, M., Vidal-Jordana, A., & Sastre-Garriga, J. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0082-z · Cited by 343
Multiple sclerosis—a quiet revolution
Ransohoff, R. M., Hafler, D. A., & Lucchinetti, C. F. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.14 · Cited by 338
Placebo-controlled trial of an oral BTK inhibitor in multiple sclerosis
Montalban, X., Arnold, D. L., Weber, M. S., Staikov, I., Piasecka-Stryczynska, K., Willmer, J., Martin, E. C., Dangond, F., Syed, S., & Wolinsky, J. S. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901981 · Cited by 324
Self-citationEvolving concepts in the treatment of relapsing multiple sclerosis
Comi, G., Radaelli, M., & Soelberg Sørensen, P. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32388-1 · Cited by 306
Epidemiology and treatment of multiple sclerosis in elderly populations
Vaughn, C. B., Jakimovski, D., Kavak, K. S., Ramanathan, M., Benedict, R. H. B., Zivadinov, R., & Weinstock-Guttman, B. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0183-3 · Cited by 306
Dimethyl fumarate in the treatment of relapsing–remitting multiple sclerosis: an overview
Bomprezzi, R. (2015) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285614564152 · Cited by 301
Molecular Basis of the KEAP1-NRF2 Signaling Pathway
Suzuki, T., Takahashi, J., & Yamamoto, M. (2023) · Molecules and Cells · doi:10.14348/molcells.2023.0028 · Cited by 301
NRF2 as a Therapeutic Target in Neurodegenerative Diseases
Brandes, M. S., & Gray, N. E. (2020) · ASN Neuro · doi:10.1177/1759091419899782 · Cited by 297
Sormani, M. P., Arnold, D. L., & De Stefano, N. (2014) · Annals of Neurology · doi:10.1002/ana.24018 · Cited by 297
Self-citationHydroxycarboxylic acid receptor 2 mediates dimethyl fumarate’s protective effect in EAE
Chen, H., Assmann, J. C., Krenz, A., Rahman, M., Grimm, M., Karsten, C. M., Köhl, J., Offermanns, S., Wettschureck, N., & Schwaninger, M. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72151 · Cited by 297
Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2
Schulze-Topphoff, U., Varrin-Doyer, M., Pekarek, K., Spencer, C. M., Shetty, A., Sagan, S. A., Cree, B. A. C., Sobel, R. A., Wipke, B. T., Steinman, L., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1603907113 · Cited by 293
Multiple Sclerosis: Immunopathology and Treatment Update
Dargahi, N., Katsara, M., Tselios, T., Androutsou, M.-E., De Courten, M., Matsoukas, J., & Apostolopoulos, V. (2017) · Brain Sciences · doi:10.3390/brainsci7070078 · Cited by 285
Comi, G., Kappos, L., Selmaj, K. W., Bar-Or, A., Arnold, D. L., Steinman, L., Hartung, H.-P., Montalban, X., Kubala Havrdová, E., Cree, B. A. C., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30239-x · Cited by 285
Self-citationOxidative Stress in Chronic Obstructive Pulmonary Disease
Barnes, P. J. (2022) · Antioxidants · doi:10.3390/antiox11050965 · Cited by 281
NRF2 promotes neuronal survival in neurodegeneration and acute nerve damage
Xiong, W., MacColl Garfinkel, A. E., Li, Y., Benowitz, L. I., & Cepko, C. L. (2015) · Journal of Clinical Investigation · doi:10.1172/jci79735 · Cited by 280
Disease‐modifying treatments for multiple sclerosis – a review of approved medications
Torkildsen, Ø., Myhr, K. ‐., & Bø, L. (2016) · European Journal of Neurology · doi:10.1111/ene.12883 · Cited by 280
Cohen, J. A., Comi, G., Selmaj, K. W., Bar-Or, A., Arnold, D. L., Steinman, L., Hartung, H.-P., Montalban, X., Kubala Havrdová, E., Cree, B. A. C., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30238-8 · Cited by 279
Self-citationMRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials
Sormani, M. P., & Bruzzi, P. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70103-0 · Cited by 278
Identifying multiple sclerosis subtypes using unsupervised machine learning and MRI data
Eshaghi, A., Young, A. L., Wijeratne, P. A., Prados, F., Arnold, D. L., Narayanan, S., Guttmann, C. R. G., Barkhof, F., Alexander, D. C., Thompson, A. J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22265-2 · Cited by 257
Self-citationTreatment strategies for multiple sclerosis: When to start, when to change, when to stop?
Gajofatto, A., & Benedetti, M. D. (2015) · World Journal of Clinical Cases · doi:10.12998/wjcc.v3.i7.545 · Cited by 256
Disease-modifying therapies and infectious risks in multiple sclerosis
Winkelmann, A., Loebermann, M., Reisinger, E. C., Hartung, H.-P., & Zettl, U. K. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.21 · Cited by 254
Kappos, L., Fox, R. J., Burcklen, M., Freedman, M. S., Havrdová, E. K., Hennessy, B., Hohlfeld, R., Lublin, F., Montalban, X., Pozzilli, C., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.0405 · Cited by 228
Self-citationChemical proteomic map of dimethyl fumarate–sensitive cysteines in primary human T cells
Blewett, M. M., Xie, J., Zaro, B. W., Backus, K. M., Altman, A., Teijaro, J. R., & Cravatt, B. F. (2016) · Science Signaling · doi:10.1126/scisignal.aaf7694 · Cited by 194
Mechanisms of white matter damage in multiple sclerosis
Lassmann, H. (2014) · Glia · doi:10.1002/glia.22597 · Cited by 191
Dulamea, A. O. (2017) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-47861-6_7 · Cited by 128
A review of the mechanisms of action of dimethylfumarate in the treatment of psoriasis
Brück, J., Dringen, R., Amasuno, A., Pau‐Charles, I., & Ghoreschi, K. (2018) · Experimental Dermatology · doi:10.1111/exd.13548 · Cited by 128
Current and emerging disease‐modulatory therapies and treatment targets for multiple sclerosis
Piehl, F. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13215 · Cited by 125
BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety
Fox, R. J., Kita, M., Cohan, S. L., Henson, L. J., Zambrano, J., Scannevin, R. H., O'Gorman, J., Novas, M., Dawson, K. T., & Phillips, J. T. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.849236 · Cited by 124
“Any AE, n (%) 333 (92) 338 (94) 316 (92) 304 (87) Most common AEs Flushing 13 (4) 110 (31) 83 (24) 6 (2) Diarrhea 28 (8) 45 (13) 50 (15) 14 (4) Nausea 29 (8) 40 (11) 51 (15) 15 (4) Upper respiratory tract infection 34 (9) 36 (10) 47 (14) 27 (8) Upper abdominal pain 17 (5) 36 (10) 33 (10) 4 (1) Proteinuria 25 (7) 29 (8…”
Self-citationWise, R. A., Holbrook, J. T., Criner, G., Sethi, S., Rayapudi, S., Sudini, K. R., Sugar, E. A., Burke, A., Thimmulappa, R., Singh, A., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0163716 · Cited by 124
Sejbaek, T., Nielsen, H. H., Penner, N., Plavina, T., Mendoza, J. P., Martin, N. A., Elkjaer, M. L., Ravnborg, M. H., & Illes, Z. (2019) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2019-321321 · Cited by 108
Yan, L., Guo, M.-S., Zhang, Y., Yu, L., Wu, J.-M., Tang, Y., Ai, W., Zhu, F.-D., Law, B. Y.-K., Chen, Q., et al. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/5288698 · Cited by 97
Hseu, Y.-C., Vudhya Gowrisankar, Y., Chen, X.-Z., Yang, Y.-C., & Yang, H.-L. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/2576823 · Cited by 81
Update on Disease-Modifying Treatments for Multiple Sclerosis
Carrithers, M. D. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.08.006 · Cited by 55
Kang, H.-J., Seo, H.-A., Go, Y., Oh, C. J., Jeoung, N. H., Park, K.-G., & Lee, I.-K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061411 · Cited by 49
Palace, J., Duddy, M., Lawton, M., Bregenzer, T., Zhu, F., Boggild, M., Piske, B., Robertson, N. P., Oger, J., Tremlett, H., et al. (2019) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2018-318360 · Cited by 44
“The RSS cohort is one of the largest cohorts ever used in a study of this type, with over 42 000 patient years of data, with 9 years or more of data for nearly 80% of patients—a dropout rate over a decade comparable with that seen in recent 2-year treatment trials.(25) 26 Moreover these results reflect the ‘real world…”
ResultThe efficacy and safety of daclizumab and its potential role in the treatment of multiple sclerosis
Milo, R. (2014) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285613504021 · Cited by 38
Cuadrado, A., Cazalla, E., Bach, A., Bathish, B., Naidu, S. D., DeNicola, G. M., Dinkova-Kostova, A. T., Fernández-Ginés, R., Grochot-Przeczek, A., Hayes, J. D., et al. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103569 · Cited by 28
Dimethyl fumarate does not mitigate cognitive decline and β-amyloidosis in female APPPS1 mice
Möhle, L., Brackhan, M., Bascuñana, P., & Pahnke, J. (2021) · Brain Research · doi:10.1016/j.brainres.2021.147579 · Cited by 21
Management of psoriasis vulgaris and multiple sclerosis with fumaric acid
Gkalpakiotis, S., Arenberger, P., Gkalpakioti, P., Meluzinova, E., Chandran, D., & Arenbergerova, M. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.10.031 · Cited by 8
Insights and challenges on animal models for progressive multiple sclerosis
Nalepa, I. F., Haahr, N. O., Bekiaris, V., Jakobsen, M. R., Asuni, A. A., & Benmamar-Badel, A. (2026) · Journal of Neuroinflammation · doi:10.1186/s12974-026-03805-3 · Cited by 1
Metadata
- Authors
- Gold, R., Kappos, L., Arnold, D. L., Bar-Or, A., Giovannoni, G., Selmaj, K., Tornatore, C., Sweetser, M. T., Yang, M., Sheikh, S. I., & Dawson, K. T.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-09-20
- Volume
- 367
- Issue
- 12
- Pages
- 1098-1107
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2093009907
- Cited by
- 1,733
- References
- 20
- FWCI
- 90.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.